Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History ACRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics ACRS

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Aclaris Therapeutics Inc

ACRS
Current price
1.59 USD +0.02 USD (+1.27%)
Last closed 1.52 USD
ISIN US00461U1051
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 171 083 984 USD
Yield for 12 month +21.37 %
1Y
3Y
5Y
10Y
15Y
ACRS
21.11.2021 - 28.11.2021

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatment of atopic dermatitis and other dermatologic conditions; Bosakitug (ATI-045), an anti-TSLP monoclonal antibody in Phase 2a trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; Zunsemetinib (ATI-450), a mitogen-activated protein kinase-activated protein kinase 2 inhibitor under Phase 1b/2 trials for the treatment of metastatic breast cancer and pancreatic ductal adenocarcinoma; and ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in preclinical stage to treat various atopic, immunologic, and respiratory diseases, as well as an ITK selective inhibitor candidate for the treatment of autoimmune diseases. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. Address: 701 Lee Road, Wayne, PA, United States, 19087

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

8.17 USD

P/E Ratio

Dividend Yield

Financials ACRS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures ACRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+18 720 000 USD

Last Year

+31 249 000 USD

Current Quarter

+1 455 000 USD

Last Quarter

+9 211 000 USD

Current Year

+3 462 000 USD

Last Year

+13 168 000 USD

Current Quarter

+949 000 USD

Last Quarter

-90 000 USD
EBITDA -53 988 000 USD
Operating Margin TTM -1 222.27 %
Price to Earnings
Return On Assets TTM -18.20 %
PEG Ratio -0.13
Return On Equity TTM -91.03 %
Wall Street Target Price 8.17 USD
Revenue TTM 17 777 000 USD
Book Value 1.33 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -39.30 %
Dividend Yield
Gross Profit TTM -32 682 000 USD
Earnings per share -1.59 USD
Diluted Eps TTM -1.59 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation ACRS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.95
Price Sales TTM 9.62
Enterprise Value EBITDA 0.28
Price Book MRQ 1.19

Technical Indicators ACRS

For 52 Weeks

1.05 USD 5.17 USD
50 Day MA 1.42 USD
Shares Short Prior Month 4 843 301
200 Day MA 1.96 USD
Short Ratio 6.78
Shares Short 7 485 345
Short Percent 5.33 %